Population Pharmacokinetic Analysis of Tacrolimus Early After Pediatric Liver Transplantation

被引:5
作者
Musuamba, Flora T. [1 ,2 ]
Guy-Viterbo, Vanessa [1 ]
Reding, Raymond [3 ]
Verbeeck, Roger K. [2 ]
Wallemacq, Pierre [1 ]
机构
[1] Catholic Univ Louvain, Louvain Ctr Toxicol & Appl Pharmacol, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Louvain Drug Res Inst, B-1200 Brussels, Belgium
[3] Catholic Univ Louvain, St Luc Univ Hosp, Transplantat Unit, B-1200 Brussels, Belgium
关键词
tacrolimus; population pharmacokinetics; pediatric liver transplantation; modeling; dose individualization; SOLID-ORGAN TRANSPLANTATION; APPARENT CLEARANCE; RECIPIENTS; PREDICTION; PHARMACODYNAMICS; POLYMORPHISMS; THERAPY; MODEL; PARAMETERS; CHILDREN;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Tacrolimus (TAC) pharmacokinetics (PKs) show considerable unexplained variability, particularly in the early period after transplantation. Therefore, TAC is a good candidate for therapeutic drug monitoring. The main objective of the present work was to propose a robust PK model for TAC in the early period after transplantation, with the final goal to provide practitioners with a tool for dose individualization in pediatric patients. Methods: TAC concentration data were obtained from 82 pediatric liver allograft recipients during the first 2 weeks after transplantation. Previously published models, and a model recently developed by our group for pediatrics early after pediatric liver transplantation, were fitted to the data and their predictive performance compared with the performances of a model developed using the data from 82 pediatric patients. Results: During the data-driven analysis, the PKs of TAC were best described by a 1-compartment model with time-varying first order elimination. Apparent volume of distribution and blood clearance estimates were 283 L and 10 L/h, respectively. The absorption was also considered to be a first order process, with a first order rate fixed to 4.45 hours. Parameters were estimated with good precision and accuracy. Although hematocrit levels, time after transplantation, liver weight, and body weight influenced the clearance, body weight was the only covariate retained on volume of central and peripheral compartments. Two of the 5 previous models showed acceptable predictive performances using the observed data. Conclusions: Time after transplantation, body weight, and hematocrit levels were shown to influence TAC PK in the early pediatric post-liver transplantation period and should be considered, besides therapeutic drug monitoring, by clinicians for the TAC posology prescription and adaptation.
引用
收藏
页码:54 / 61
页数:8
相关论文
共 32 条
[1]   Measurement of tacrolimus (FK506) and its metabolites: A review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies [J].
Alak, AM .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :338-351
[2]   Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance [J].
Antignac, M ;
Hulot, JS ;
Boleslawski, E ;
Hannoun, L ;
Touitou, Y ;
Farinotti, R ;
Lechat, P ;
Urien, S .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (5-6) :409-416
[3]   Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters [J].
Bertrand, Julie ;
Comets, Emmanuelle ;
Mentre, France .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (06) :1084-1102
[4]   Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period [J].
Blanchet, Benoit ;
Duvoux, Christophe ;
Costentin, Charlotte E. ;
Barrault, Camille ;
Ghaleh, Bijan ;
Salvat, Annie ;
Jouault, Helene ;
Astier, Alain ;
Tod, Michel ;
Hulin, Anne .
THERAPEUTIC DRUG MONITORING, 2008, 30 (04) :412-418
[5]   Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models:: The npde add-on package for R [J].
Comets, Emmanuelle ;
Brendel, Karl ;
Mentre, France .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2008, 90 (02) :154-166
[6]   NUCLEAR-ASSOCIATION OF A T-CELL TRANSCRIPTION FACTOR BLOCKED BY FK-506 AND CYCLOSPORINE-A [J].
FLANAGAN, WM ;
CORTHESY, B ;
BRAM, RJ ;
CRABTREE, GR .
NATURE, 1991, 352 (6338) :803-807
[7]  
Fukatsu S, 2001, EUR J CLIN PHARMACOL, V57, P479
[8]   Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients [J].
Fukudo, Masahide ;
Yano, Ikuko ;
Masuda, Satohiro ;
Goto, Maki ;
Uesugi, Miwa ;
Katsura, Toshiya ;
Ogura, Yasuhiro ;
Oike, Fumitaka ;
Takada, Yasutsugu ;
Egawa, Hiroto ;
Uemoto, Shinji ;
Inui, Ken-ichi .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (04) :331-345
[9]   Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation [J].
Guy-Viterbo, V. ;
Scohy, A. ;
Verbeeck, R. K. ;
Reding, R. ;
Wallemacq, P. ;
Musuamba, Flora Tshinanu .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (08) :1533-1542
[10]   Conditional weighted residuals (CWRES): A model diagnostic for the FOCE method [J].
Hooker, Andrew C. ;
Staatz, Christine E. ;
Karlsson, Mats O. .
PHARMACEUTICAL RESEARCH, 2007, 24 (12) :2187-2197